Araris has a pipeline that includes three ADC candidates targeting hematological and solid tumors, with clinical trials expected to begin between 2025 and 2026.
Organizations Involved
Taiho Pharmaceutical
Founders
Dr. Dragan Grabulovski, Isabella Attinger-Toller, Philipp Spycher
Company Description
Araris Biotech is a Swiss biotechnology company known for developing next-generation antibody-drug conjugates (ADCs) through its proprietary platform, AraLinQ™, which improves the design, stability, and manufacturing of ADCs, aiming to offer treatments with better safety profiles and enhanced effectiveness.